TY - JOUR
T1 - Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study
AU - Dabestani, Saeed
AU - Azawi, Nessn H
AU - Campi, Riccardo
AU - Järvinen, Petrus
AU - Nisen, Harry
AU - Capitanio, Umberto
AU - Nielsen, Tommy Kjærgaard
AU - Simone, Giuseppe
AU - Rochester, Mark
AU - Green, Euan
AU - Fernandez-Pello, Sergio
AU - Blick, Christopher
AU - Porpiglia, Francesco
AU - Ingels, Alexandre
AU - Bratulic, Sinisa
AU - Antonelli, Alessandro
AU - Hakimi, A Ari
AU - Jewett, Michael A S
AU - Ljungberg, Börje
AU - Bhindi, Bimal
AU - Marconi, Lorenzo
AU - Laird, Alexander
AU - Stewart, Grant D
AU - Nair, Rajesh
AU - Lund, Lars
AU - Barber, Neil
AU - Master, Viraj A
AU - Minervini, Andrea
AU - Karam, Jose A
AU - Gatto, Francesco
AU - Bex, Axel
N1 - Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
PY - 2025
Y1 - 2025
N2 - BACKGROUND AND OBJECTIVE: Nonmetastatic (M0) clear cell renal cell carcinoma (ccRCC) recurs in ∼20% of patients within 5 yr after surgery. With no biomarkers available, recurrence detection relies on radiological imaging. Urine glycosaminoglycan profiles (GAGomes) were previously associated with M0 ccRCC recurrence. We conducted an observational prospective multicentre diagnostic test cohort study to evaluate GAGomes for postsurgery recurrence detection in M0 ccRCC.METHODS: Postsurgical M0 ccRCC patients with a Leibovich score of ≥5 points were included. Follow-up imaging up to 18 mo assessed radiological recurrence (reference standard). Urine GAGomes were measured every 3 mo to compute a GAGome score (index test). Sensitivity and specificity to radiological recurrence were calculated. The lead time between the first positive GAGome score and radiological recurrence was estimated. Bayesian joint modelling estimated recurrence-free survival hazard ratio (HR).KEY FINDINGS AND LIMITATIONS: Of the 393 patients screened (January 2020 to November 2021), 134 met the inclusion criteria. The median follow-up was 16 mo (interquartile range [IQR]: 12-18) for those without recurrence. At the last follow-up visit, 16% had recurred. The GAGome score had 90% sensitivity (95% confidence interval [CI]: 62-100%) and 51% specificity (95% CI: 30-71%) to radiological recurrence. The positive and negative predictive values were 26% (95%CI: 4-46%) and 97% (95% CI: 87-100%), respectively. The median lead time was 4.2 mo (IQR: 1.6-6.4). A 10-point GAGome score increase was associated with an HR of 1.62 (95% high density interval: 1.11-2.30) for recurrence. The main limitation was short follow-up time.CONCLUSIONS AND CLINICAL IMPLICATIONS: GAGome score had very high sensitivity to ccRCC recurrence, resulting in a negative predictive value of 97%. External validation foreseen in the study design aims to confirm its utility to personalise follow-up for M0 ccRCC patients.
AB - BACKGROUND AND OBJECTIVE: Nonmetastatic (M0) clear cell renal cell carcinoma (ccRCC) recurs in ∼20% of patients within 5 yr after surgery. With no biomarkers available, recurrence detection relies on radiological imaging. Urine glycosaminoglycan profiles (GAGomes) were previously associated with M0 ccRCC recurrence. We conducted an observational prospective multicentre diagnostic test cohort study to evaluate GAGomes for postsurgery recurrence detection in M0 ccRCC.METHODS: Postsurgical M0 ccRCC patients with a Leibovich score of ≥5 points were included. Follow-up imaging up to 18 mo assessed radiological recurrence (reference standard). Urine GAGomes were measured every 3 mo to compute a GAGome score (index test). Sensitivity and specificity to radiological recurrence were calculated. The lead time between the first positive GAGome score and radiological recurrence was estimated. Bayesian joint modelling estimated recurrence-free survival hazard ratio (HR).KEY FINDINGS AND LIMITATIONS: Of the 393 patients screened (January 2020 to November 2021), 134 met the inclusion criteria. The median follow-up was 16 mo (interquartile range [IQR]: 12-18) for those without recurrence. At the last follow-up visit, 16% had recurred. The GAGome score had 90% sensitivity (95% confidence interval [CI]: 62-100%) and 51% specificity (95% CI: 30-71%) to radiological recurrence. The positive and negative predictive values were 26% (95%CI: 4-46%) and 97% (95% CI: 87-100%), respectively. The median lead time was 4.2 mo (IQR: 1.6-6.4). A 10-point GAGome score increase was associated with an HR of 1.62 (95% high density interval: 1.11-2.30) for recurrence. The main limitation was short follow-up time.CONCLUSIONS AND CLINICAL IMPLICATIONS: GAGome score had very high sensitivity to ccRCC recurrence, resulting in a negative predictive value of 97%. External validation foreseen in the study design aims to confirm its utility to personalise follow-up for M0 ccRCC patients.
KW - Humans
KW - Carcinoma, Renal Cell/urine
KW - Female
KW - Male
KW - Prospective Studies
KW - Middle Aged
KW - Glycosaminoglycans/urine
KW - Neoplasm Recurrence, Local/urine
KW - Kidney Neoplasms/urine
KW - Aged
KW - Cohort Studies
U2 - 10.1016/j.euo.2025.07.011
DO - 10.1016/j.euo.2025.07.011
M3 - Journal article
C2 - 40866172
SN - 2588-9311
VL - 8
SP - 1566
EP - 1574
JO - European urology oncology
JF - European urology oncology
IS - 6
ER -